Multimodality therapy of early-stage (FIGO I-II) ovarian cancer

Review of surgical management and postoperative adjuvant treatment

N. Colombo, A. Maggioni, L. Bocciolone, S. Rota, M. G. Cantu, C. Mangioni

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Two surgical aspects in the treatment of early-stage ovarian cancer deserve attention: the likelihood of retroperitoneal node involvement and the possibility of conservative surgery in young patients who desire to preserve reproductive function. Although lymph node involvement has been thought to be infrequent in ovarian cancer, recent reports have documented retroperitoneal node metastases in 9.5-25% of patients with early-stage ovarian cancer. A current prospective randomized trial in Italy, comparing systematic para- aortic and pelvic lymphadenectomy with sample biopsies of retroperitoneum in patients with early disease, should reveal whether systematic lymphadenectomy merely adds to knowledge of the natural history of the disease or whether it will influence subsequent therapy and prognosis. Most researchers agree that conservative surgery should be performed in young patients with borderline tumors and stage I, grade 1 ovarian cancer. Our experience over a 10-year period in which 56% of 99 women aged 32P treatment. These results suggested the design of a currently ongoing multicenter trial testing platinum-based therapy soon after surgery or at time of relapse.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume6
Issue number5 SUPPL. 1
Publication statusPublished - 1996

Fingerprint

Ovarian Neoplasms
Lymph Node Excision
Therapeutics
Platinum
Italy
Multicenter Studies
Lymph Nodes
Research Personnel
Neoplasm Metastasis
Biopsy
Recurrence
Neoplasms

Keywords

  • adjuvant therapy
  • multimodality therapy
  • ovarian cancer
  • surgery

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynaecology
  • Oncology

Cite this

Multimodality therapy of early-stage (FIGO I-II) ovarian cancer : Review of surgical management and postoperative adjuvant treatment. / Colombo, N.; Maggioni, A.; Bocciolone, L.; Rota, S.; Cantu, M. G.; Mangioni, C.

In: International Journal of Gynecological Cancer, Vol. 6, No. 5 SUPPL. 1, 1996, p. 13-17.

Research output: Contribution to journalArticle

@article{2457406038b440a2aea365f59cd28a81,
title = "Multimodality therapy of early-stage (FIGO I-II) ovarian cancer: Review of surgical management and postoperative adjuvant treatment",
abstract = "Two surgical aspects in the treatment of early-stage ovarian cancer deserve attention: the likelihood of retroperitoneal node involvement and the possibility of conservative surgery in young patients who desire to preserve reproductive function. Although lymph node involvement has been thought to be infrequent in ovarian cancer, recent reports have documented retroperitoneal node metastases in 9.5-25{\%} of patients with early-stage ovarian cancer. A current prospective randomized trial in Italy, comparing systematic para- aortic and pelvic lymphadenectomy with sample biopsies of retroperitoneum in patients with early disease, should reveal whether systematic lymphadenectomy merely adds to knowledge of the natural history of the disease or whether it will influence subsequent therapy and prognosis. Most researchers agree that conservative surgery should be performed in young patients with borderline tumors and stage I, grade 1 ovarian cancer. Our experience over a 10-year period in which 56{\%} of 99 women aged 32P treatment. These results suggested the design of a currently ongoing multicenter trial testing platinum-based therapy soon after surgery or at time of relapse.",
keywords = "adjuvant therapy, multimodality therapy, ovarian cancer, surgery",
author = "N. Colombo and A. Maggioni and L. Bocciolone and S. Rota and Cantu, {M. G.} and C. Mangioni",
year = "1996",
language = "English",
volume = "6",
pages = "13--17",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Multimodality therapy of early-stage (FIGO I-II) ovarian cancer

T2 - Review of surgical management and postoperative adjuvant treatment

AU - Colombo, N.

AU - Maggioni, A.

AU - Bocciolone, L.

AU - Rota, S.

AU - Cantu, M. G.

AU - Mangioni, C.

PY - 1996

Y1 - 1996

N2 - Two surgical aspects in the treatment of early-stage ovarian cancer deserve attention: the likelihood of retroperitoneal node involvement and the possibility of conservative surgery in young patients who desire to preserve reproductive function. Although lymph node involvement has been thought to be infrequent in ovarian cancer, recent reports have documented retroperitoneal node metastases in 9.5-25% of patients with early-stage ovarian cancer. A current prospective randomized trial in Italy, comparing systematic para- aortic and pelvic lymphadenectomy with sample biopsies of retroperitoneum in patients with early disease, should reveal whether systematic lymphadenectomy merely adds to knowledge of the natural history of the disease or whether it will influence subsequent therapy and prognosis. Most researchers agree that conservative surgery should be performed in young patients with borderline tumors and stage I, grade 1 ovarian cancer. Our experience over a 10-year period in which 56% of 99 women aged 32P treatment. These results suggested the design of a currently ongoing multicenter trial testing platinum-based therapy soon after surgery or at time of relapse.

AB - Two surgical aspects in the treatment of early-stage ovarian cancer deserve attention: the likelihood of retroperitoneal node involvement and the possibility of conservative surgery in young patients who desire to preserve reproductive function. Although lymph node involvement has been thought to be infrequent in ovarian cancer, recent reports have documented retroperitoneal node metastases in 9.5-25% of patients with early-stage ovarian cancer. A current prospective randomized trial in Italy, comparing systematic para- aortic and pelvic lymphadenectomy with sample biopsies of retroperitoneum in patients with early disease, should reveal whether systematic lymphadenectomy merely adds to knowledge of the natural history of the disease or whether it will influence subsequent therapy and prognosis. Most researchers agree that conservative surgery should be performed in young patients with borderline tumors and stage I, grade 1 ovarian cancer. Our experience over a 10-year period in which 56% of 99 women aged 32P treatment. These results suggested the design of a currently ongoing multicenter trial testing platinum-based therapy soon after surgery or at time of relapse.

KW - adjuvant therapy

KW - multimodality therapy

KW - ovarian cancer

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=0029779257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029779257&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 13

EP - 17

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5 SUPPL. 1

ER -